Sign in
Not yet recruitingPhase 2/3

Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza

Key facts

Who runs it
Capital Medical University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
570 people, planned
Started
21 Oct 2026
Expected to end
30 Mar 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • 20 mg 102D-6 dry suspension
  • 40 mg 102D-6 dry suspension
  • Placebo
Record updated
26 October 2026

Who can take part

Age
12 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 18 to 65 years (including cut-off value), male or female
  • Patients in the screening period met the following criteria:; Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; Pyrexial (axillary temperature ≥ 37.3 °C). If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours); At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points; At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points
  • The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization
  • Aged 12 to 65 years (including cut-off value), male or female
  • Patients in the screening period met the following criteria:; Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; Fever ≥ 37.3 °C(axillary temperature) at Screening. If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours); At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points; At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points
  • The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization
  • Aged 18 to 65 years (including cut-off value), male or female
  • Patients in the screening period met the following criteria:; Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; Pyrexial (axillary temperature ≥ 37.3 °C). If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours); At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points; At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points
  • The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization
  • Aged 12 to 65 years (including cut-off value), male or female; 2.Patients in the screening period met the following criteria:
  • Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive
  • Fever ≥ 37.3 °C(axillary temperature) at Screening. If antipyretic drugs (including Chinese patent medicines) are taken, the axillary temperature should be ≥ 37.3 °C after administration(more than 4 hours)
  • At least one Influenza viral infections-related General symptoms (Headache, Pyrexial or chills, muscle or Soreness of joint, Lassitude) score ≥ 2 points
  • At least one Influenza viral infections-related respiratory symptom (Coughing, Pharyngalgia, Nasal obstruction) score ≥ 2 points; 3.The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 12 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this Phase II/III study is to investigate the safty and efficacy of 102D-6 in adolescents and adults with influenza.

Read full original descriptionShow less

The main aim to answer:

1. Phase II study is to evaluate the efficacy of 102D-6 in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. The results will be used to design the Phase III study. 2. Phase III study is to evaluate the efficacy of 102D-6 by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza.

Participants will be taken 102D-6/Placebo once, and be observed by 15 days.

The 3 groups in the trial

  • 102D-6 low dose groupTreatment being tested

    20 mg of 102D-6 dry suspension Once during the whole study. Based on the analysis of phase II, arms not selected will be discontinued

    Treatment: 20 mg 102D-6 dry suspension

  • 102D-6 high dose groupTreatment being tested

    40 mg of 102D-6 dry suspension Once during the whole study. Based on the analysis of phase II, arms not selected will be discontinued

    Treatment: 40 mg 102D-6 dry suspension

  • Placebo controlPlacebo, for comparison

    Analog dry suspension with no active ingredient.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of 102D-6 in the Treatment of Uncomplicated Influenza.
Criteria questions
Built from NCT07893847, who can take part
Record updated
26 October 2026